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were excluded (7177 patients were included). 
Significant reductions in stent thrombosis with 
continued thienopyridine, as compared with 
placebo, were observed within 3 months after 
randomization (0% vs. 0.23%, P = 0.01), and the 
difference increased over the 12-to-30-month 
treatment period (0.23% vs. 0.72%; hazard ratio, 
0.33; 95% CI, 0.15 to 0.72; P = 0.004). Further-
more, in this subgroup analysis, as in the pri-
mary analysis, continued thienopyridine was 
associated with a larger absolute risk reduction 
for myocardial infarction that was not related to 
stent thrombosis (absolute difference, 0.81 per-
centage points), as compared with the risk re-
duction for the end point of stent thrombosis. 
These findings highlight the relevance of the 
study results to current coronary procedures and 
secondary prevention of myocardial infarction.
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Multiple-System Atrophy
To the Editor: Fanciulli and Wenning’s review 
(Jan. 15 issue)1 on multiple-system atrophy is 
comprehensive and up to date. In it, the authors 
state that the open-label administration of gaba-
pentin could ameliorate cerebellar symptoms in 
single cases of this disease. However, the cited 
reference describes a noticeable improvement in 
gait in one patient who received a diagnosis of 
olivopontocerebellar atrophy (OPCA) after a sin-
gle dose of 400 mg of gabapentin and alleviation 
of dysarthria and oscillopsia in another patient 
with OPCA during long-term therapy with gaba-
pentin.2 These patients could not have received a 
diagnosis of multiple-system atrophy, since nei-
ther had features of autonomic dysfunction.3 In 
contrast, gabapentin was found to cause general-
ized weakness and to worsen gait and dysarthria 
in three patients with multiple-system atrophy, 
forcing withdrawal of the drug.4 
The reasons for the differing effectiveness 
of gabapentin in patients with multiple-system 
atrophy (a primary oligodendroglial α-synu-
cleinopathy) and OPCA (a neuronopathy of the 
cerebellar cortex, inferior olive, and pontine 
nuclei)5 could depend on differences in patho-
physiology or neurochemistry between these 
diseases, although the precise cause remains 
undetermined.
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To the Editor: In their review, Fanciulli and 
Wenning point out that urinary dysfunction is a 
key feature of multiple-system atrophy, with ur-
gency, daytime frequency, and nocturia being the 
most common urinary symptoms. However, it 
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should be noted that although overactive bladder 
is a common feature in Parkinson’s disease, mul-
tiple-system atrophy is far more frequently char-
acterized by detrusor underactivity, dyssynergic 
urethral function, and incomplete bladder emp-
tying alone or in association with storage symp-
toms.1 This could be related in part to cell loss 
affecting the Onuf nucleus, which is usually 
spared in Parkinson’s disease.2 α-Adrenergic 
blockers can be prescribed to improve bladder 
emptying, as advocated in the review, but they 
should be used with extreme caution because of 
the autonomic failure with orthostatic hypoten-
sion present in most patients and the inherent 
risk of syncope with α-adrenergic antagonist 
medication.3 Clean, intermittent self-catheteriza-
tion is the mainstay of management of bladder-
emptying problems if allowed by the patient’s 
motor impairment; the safety profile is excellent, 
and the problems of urethral ulceration described 
in the article are rare.4
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To the Editor: I read with interest Fanciulli and 
Wenning’s review but was dismayed by the state-
ment that placement of a percutaneous endo-
scopic gastrostomy tube lowers the risk of aspi-
ration pneumonia. This widely held idea has 
never been proved to be true. As Marik pointed 
out,1 feeding tubes cannot protect against con-
taminated oral secretions, a major risk factor for 
the development of pneumonia. In addition, pa-
tients with percutaneous endoscopic gastrosto-
my tubes have frequent gastroesophageal reflux, 
more commonly in those with neurologic versus 
mechanical dysphagia.2 One study involving pa-
tients in nursing homes showed that tube feed-
ing was an independent risk factor for the devel-
opment of aspiration pneumonia, with an odds 
ratio of 3.0.3
In a review of tube feeding in patients with 
advanced dementia, Finucane et al.4 found no 
data to support this intervention, a conclusion 
that is likely to be applicable in the setting of 
progressive neurodegenerative disease. For pa-
tients with multiple-system atrophy, tube feed-
ing is unlikely to be helpful and could poten-
tially be harmful.
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The Authors Reply: In response to Gazulla and 
Berciano: to date, there is no symptomatic treat-
ment available for cerebellar ataxia associated 
with multiple-system atrophy. Gazulla and col-
leagues previously found class IV evidence for the 
efficacy of gabapentin in OPCA, a nosologic en-
tity that may evolve into multiple-system atrophy 
of the cerebellar subtype. Gazulla and colleagues 
subsequently found side effects of open-label 
gabapentin or pregabalin administration in three 
patients with multiple-system atrophy (class IV 
evidence). We conclude that the currently avail-
able evidence regarding the safety and efficacy of 
gabapentin in multiple-system atrophy is insuf-
ficient.
Urge incontinence was reported more fre-
quently than incomplete bladder emptying in two 
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epidemiologic cohorts of patients with multiple-
system atrophy, with simultaneous occurrence 
in one third of cases.1,2 Clean, intermittent self-
catheterization is the first-line therapy for uri-
nary retention of more than 100 ml, and 
α1-adrenoreceptor blockers have been proposed 
as add-on therapy.3 We agree with Peyronnet and 
colleagues that α1-adrenoreceptor blockers should 
be used cautiously in patients with multiple-
system atrophy owing to exacerbation of ortho-
static hypotension. Tamsulosin may be preferred 
to other α1-adrenoreceptor blockers, given a 
higher selectivity for prostatic α1-adrenorecep-
tors.4 Evening scheduling of α1-adrenoreceptor 
blockers is preferred in order to minimize hypo-
tensive side effects and to manage nocturnal 
hypertension in affected patients. Nocturnal use 
of urine condoms can represent an additional 
safety measure to prevent orthostatic syncope 
in patients with nocturia and orthostatic hypo-
tension.
In response to Babu: aspiration pneumonia is 
the most common cause of death in multiple-
system atrophy. In patients with severe dyspha-
gia, tube feeding may be necessary to prevent 
choking, provide adequate caloric intake, and 
reduce the amount of aspirated oropharyngeal 
material. It cannot, however, prevent the aspira-
tion of oral secretion. To this end, strategies 
aimed at reducing saliva production could be 
implemented (e.g., botulinum-toxin injection 
into salivary glands or scopolamine transdermal 
patch), but evidence for the safety and efficacy of 
such approaches is limited in multiple-system 
atrophy.
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Severe Ebola Virus Infection Complicated by Gram-Negative 
Septicemia
To the Editor: The World Health Organization 
(WHO) recently published its first global report 
on antimicrobial resistance surveillance.1 For 
countries in the WHO African region, the pro-
portions of invasive Escherichia coli isolates that 
were antimicrobial-resistant ranged from 0 to 
36% for third-generation cephalosporins and 
from 0 to 53% for fluoroquinolones. In the past 
few years, studies from Europe and Canada have 
consistently shown that fecal colonization by 
multidrug-resistant Enterobacteriaceae is com-
mon in returning international travelers (with 
rates of 22 to 53% among travelers returning 
from Africa).2-4 These generally were E. coli iso-
lates that produced an extended-spectrum beta-
lactamase and were resistant to third-generation 
cephalosporins as well as to several other classes 
of antibiotic agents including fluoroquinolones. 
As suggested by Kreuels et al. (Dec. 18 issue),5 
sepsis that is likely to be due to bacterial translo-
cation may complicate Ebola virus disease (EVD) 
and contribute to mortality. While treating clini-
cians await the results of blood cultures, empiri-
cal antimicrobial treatment of sepsis should take 
into account the consideration of fecal coloniza-
tion by multidrug-resistant Enterobacteriaceae in 
patients with EVD who were treated in or medi-
cally evacuated from Africa.
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